IP Library Granted Patent US 11,464,748
Granted Patent B2
US 11,464,748 · App. 16/074,643 · Granted Oct 11, 2022

Particles for targeted delivery and uses in managing bleeding or blood clotting

Inventors: Wilbur A. Lam (Decatur, GA); Caroline Hansen (Atlanta, GA); Yumiko Sakurai (Atlanta, GA); Andrew Lyon (Irvine, CA)
Assignees: Emory University; Children's Healthcare of Atlanta, Inc.; Georgia Tech Research Corporation; Chapman University
A61K9/5031A61K9/5036A61K9/5073A61K9/5089A61K38/37
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,464,748
App. No.
16/074,643
Granted
Oct 11, 2022
Kind
B2
Abstract

This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.

Claims (6)

1. A particle having a core comprising factor VIII encapsulated in a coating comprising:

a) a cationic polymer layer, wherein the cationic polymer layer comprises poly-L-lysine;

b) an anionic polymer layer, wherein the anionic polymer layer comprises poly-L-glutamic acid, and the cationic polymer layer is over a polysaccharide layer;

c) an outer layer exposing fibrinogen on the outer surface, wherein the anionic polymer layer is under the outer layer; and

wherein the polysaccharide is a dextran.

2. A pharmaceutical composition comprising a particle of claim 1 and a pharmaceutically acceptable excipient.

Assignments (1)
CONFIRMATORY LICENSE Recorded Nov 21, 2018
From: EMORY UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047561/0476 →
Continuity (2)
Provisional Application 62289642 · Feb 1, 2016
Related Publication 20200306199A1 · Oct 1, 2020